EQT

eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

Storytel AB provides streaming services for audiobooks and e-books through subscription models, operating under the Storytel and Mofibo brands. Founded in 2005, the company has established itself as a leader in this sector across various countries, including Sweden, Norway, Denmark, Finland, the Netherlands, Poland, Germany, Spain, and India, among others. In addition to its streaming services, Storytel publishes audiobooks primarily through its own publisher, Storyside, and has expanded its reach in the publishing industry by acquiring several publishing houses such as Massolit and B. Wahlström. The company also offers digital subscriptions for newspapers and magazines and publishes physical books through notable imprints like Norstedts and Rabén & Sjögren. Headquartered in Stockholm, Sweden, Storytel continues to enhance its offerings in the growing digital reading and listening market.

Mollie B.V. provides online payments processing services to merchants. Its features include integration of all payment methods into one platform; business plan creation for receiving recurring payments; and accepting multicurrency payments. The company was founded in 2004 and is headquartered in Amsterdam, the Netherlands.

Founded in 1990, Desotec has pioneered the market for the purification of liquids and gases through mobile activated carbon filters. During its more than 25 years in business, the company has established itself as a European market leader in this field. Desotec provides a filtration technology that enables its customers to comply with increased environmental regulations and sustainability requirements and to serve mission-critical filtration needs offering a flexible rental solution.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

Vico Therapeutics is a developer of ribonucleic acid (RNA) modulating therapies for rare neurological disorders. The company discovers, develops, and delivers therapies for CNS disorders. Its initial focus is on SCA which is a subgroup of hereditary ataxia, HD which is a neurodegenerative disorder, and RTT-a neurodevelopmental disorder primarily affecting girls that enable clients with providing therapy for it. Vico Therapeutics was founded in 2019 by Luc Dochez, Josh Mandel-Brehm, Judith van Deutekom, and Gail Mandel and it is headquartered in Leiden, The Netherlands.

VarmX B.V., a biotechnology company, develops therapies in the field of hemostasis and thrombosis. It develops PseudoXa, a therapeutic protein that is used to stop bleeding of patients who use blood thinners. The company was founded in 2016 and is based in Leiden, the Netherlands.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

A fully licensed bank, Banking Circle is a next-generation provider of mission-critical financial services infrastructure leading the rise of a super-correspondent banking network. Banks and Payments businesses can access a range of banking services - multi-currency bank accounts, local clearing, cross border payments and flexible business lending, compliantly and securely - without the need to build their own infrastructure and correspondent banking partner network. Bespoke, flexible, scalable and futureproofed solutions enable financial services businesses to do what they’re really good at – serving the end client successfully and efficiently – thereby allowing them to seize market opportunities. Bypass old, bureaucratic and expensive systems and enable global banking services for your clients. Financial infrastructure you can bank on.

Dunlop Protective Footwear is the leading global manufacturer of protective wellington boots. In more than 50 countries worldwide, the Company provides comfortable and protective footwear to the workers in Agriculture & Fishery, Food processing, Industry and the Oil, Gas & Mining industry. Dunlop has more than 500 employees, three production sites in the Netherlands, Portugal and the US, and sales people around the world. Dunlop Protective Footwear is headquartered in Raalte, the Netherlands.

Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Caiway is a telecom infrastructure company based in Naaldwijk, Netherlands, specializing in broadband, television, and telephony services. The company operates broadband connections to over 350,000 households and businesses, focusing on both urban and remote areas. In recent years, Caiway has expanded its fiber networks to enhance connectivity in municipalities and homes, establishing itself as a strong regional internet service provider. Key regions within Caiway's service area include Westland, Schiedam, and Almelo. By leveraging advanced cable and fiber infrastructure, Caiway aims to deliver reliable networking and high-quality services to its customers.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

DentConnect is a fast-growing platform of dental clinics, with activities in the Netherlands, Belgium, Denmark, Germany and Italy. DentConnect is headquartered in the Netherlands and serves over one million patients through its pan-European network of over 220 clinics. DentConnect acts as a multi-functional service organization for these clinics, allowing the dentists to fully focus on providing patients with the best possible care. DentConnect Shared Service Center supports and facilitates dentists with HR, Finance and administration, quality and care management, procurement, marketing and communication and general management.

Founded in 1990, Desotec has pioneered the market for the purification of liquids and gases through mobile activated carbon filters. During its more than 25 years in business, the company has established itself as a European market leader in this field. Desotec provides a filtration technology that enables its customers to comply with increased environmental regulations and sustainability requirements and to serve mission-critical filtration needs offering a flexible rental solution.

Delta Comfort offers multimedia and energy solutions to residential and business clients in the province of Zeeland. Delta Comfort owns and operates a hybrid fiber-coaxial (HFC) network of 3,400km of fiber and 3,000km of coaxial cables, which passes 192,000 households in the region. Delta Comfort employs approximately 370 people and generated sales of EUR 214 million in 2015. It is headquartered in Middelburg, the capital of Zeeland, Netherlands.

TransIP Group B.V. provides virtual private servers, domain name registration, and Web hosting services to customers and information technology professionals. The company offers BladeVPS PureSSD Pro, a self-managed tool that contains Web control panels and operating systems; STACK, an online storage solution for storing, syncing, and sharing various files, photos, and documents; and SSL certificates that encrypt the connection between a Website and the server. It also offers forwarding, big storage, and private network services. The company was founded in 2003 and is based in Leiden, the Netherlands. As of May 23, 2019, TransIP Group B.V. operates as a subsidiary of Combell nv.

Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Onward is developing an Implantable Neuro-stimulation System (INS) with real-time motion feedback and uses training tools to rehabilitate patients suffering from neurological disorders such as spinal cord injury (SCI).

eTheRNA immunotherapies' mission is to help patients to overcome certain cancers and infectious diseases by developing novel immunotherapies that target the fundamental role of dendritic cells in the human immune system. eTheRNA’s proprietary mRNA-based TriMix technology boosts dendritic cells leading to a more comprehensive, sustainable and safer enhancement of the patient’s immune system than any other similar approach investigated until now.

ViCentra, they like to keep things simple. ViCentra believe that if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. Creating brilliant products doesn’t end at the manufacturing line though – they also believe in the power of great customer experiences. From our offices in the Netherlands and UK, they’re creating healthcare products with this philosophy firmly in mind. They don’t design for patients – they design for people.

Pharvaris B.V. is a clinical-stage company based in Leiden, the Netherlands, focused on the discovery and development of oral bradykinin B2 receptor antagonists for the treatment of hereditary angioedema (HAE) and other conditions linked to B2 receptor activity. Established in 2015, the company aims to provide new therapeutic options that eliminate the need for injections. Its lead drug candidate, PHA121, is a novel small-molecule antagonist currently undergoing Phase 1 clinical trials. Pharvaris benefits from the expertise of its co-founders, including an inventor of icatibant, which is a previously developed treatment for HAE. The company is dedicated to advancing alternatives to existing therapies, enhancing the quality of life for patients with HAE.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

Neuravi Limited is a medical device company based in Galway, Ireland, focused on developing clot retrieval devices to restore blood flow in patients who have experienced ischemic strokes caused by arterial blockages in the brain. The company offers the EmboTrap revascularization devices, which are designed for the treatment of acute ischemic strokes and are available in several European countries, including Belgium, Denmark, France, Germany, and Spain. Founded in 2009, Neuravi operates in the emerging neurointerventional device market and collaborates with researchers and clinicians to advance treatment solutions for this serious condition. As of April 2017, Neuravi is a subsidiary of DePuy Ireland Unlimited Company.

Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Xeltis AG operates as a clinical-stage medical device company that develops bio-absorbable heart valves and blood vessels. The company’s RestoreX, a polymer-based technology enables the patient's natural healing system to develop tissue that pervades Xeltis' heart valve, forming a new functional valve within it through a therapeutic approach called Endogenous Tissue Restoration (ETR). Xeltis AG was founded in 2006 and is headquartered in Zurich, Switzerland with an additional R&D and manufacturing location in Eindhoven, the Netherlands.

Bureau van Dijk is best known for our range of company information products that is co-published with many renowned information providers (IPs).

Mint Solutions develops MedEye, a solution for medication and patient safety in hospitals and other healthcare institutions. MedEye helps nurses verify and document all medication administrations to patients. The solution uses computer vision technology to enable the nurse to work faster and more efficiently than other comparable solutions. MedEye integrates with hospital information systems to retrieve information about which medications patients should be getting. MedEye then works with the nurse to make sure that all medication dosages are safely delivered to the patient. Without requiring the nurse to type information or use a computer, MedEye then safely documents all actions and completes the medical history of the patient. MedEye addresses the problem of medication errors in hospitals and healthcare institutions. It is estimated that 1 in 5 medications are given incorrectly in hospitals, causing one medication error per patient per day.

Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

BSN medical is a global leader in the worldwide healthcare market specialising in the areas of Compression Therapy, Wound Care and Orthopaedics. We are focused on the development of world-class branded products that offer high quality solutions for our caregivers and patients. BSN medical connects its broad portfolio in Wound Care & related Vascular Diseases, Lymphology and non-invasive Orthopaedics with strong technological competencies to meet the market's need for reduced complexity and more efficient treatments. With a continuously developing unique and holistic network integrated therapy solutions, BSN medical consistently supports a continuum of care.

Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

Atos Medical was founded in 1986 and today has a vast international network with subsidiaries in the USA, UK, Germany, Spain, Netherlands, Belgium, Sweden and Switzerland and also exclusive distributors serving about 60 countries. The head office is situated in Sweden, where a state-of-the-art clean room and laboratory make it possible to perform all tests required for successful R&D.

Sapiens Steering Brain Stimulation GmbH is an emerging medical device company whose mission is to deliver superior solutions for deep brain stimulation (DBS) therapy. Sapiens' ambition is to provide a unique, high-resolution, and MRI- compatible DBS system that will improve patient comfort and therapeutic outcome, initially for patients with Parkinson's disease. Sapiens, with offices in Eindhoven, the Netherlands and Munich, Germany, is founded in 2011 as a spin-out of Royal Philips Electronics. Its steering brain stimulation (SBS) system and image-guided programming are based upon patented technologies.

Koole is an independent international storage and transport company specialising in vegetable oils and fats, oleochemicals, waxes, biodiesel, base oils, non-hazardous chemicals and minerals.

Promethera® Biosciences is a biopharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatments based on allogeneic adult stem cell technology. Promethera® Biosciences' mission is to discover, develop and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type: the human Adult Liver-Derived Mesenchymal Progenitor Cell (hALDMSC):

Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.

Merus N.V. is a clinical-stage immuno-oncology company based in the Netherlands, focused on the discovery and development of bispecific antibody therapeutics. The company's pipeline includes several promising candidates, notably MCLA-128, currently in phase 2 clinical trials for metastatic breast cancer; MCLA-117, in phase I trials for acute myeloid leukemia; and MCLA-158, also in phase I trials for solid tumors. Additionally, Merus is advancing other bispecific antibody candidates, including MCLA-129 and MCLA-145, in collaboration with various pharmaceutical partners. The company employs a unique technology called Oligoclonics, which enables the production of a mixture of therapeutic antibodies from a single cell clone, aimed at targeting common antigens. Merus has established partnerships to enhance its research capabilities, such as its collaboration with Caris Life Sciences for detecting NRG1 fusions in cancer patients. Founded in 2003, Merus is headquartered in Utrecht and is dedicated to developing innovative treatments for cancer.

Kreatech Holding BV is a molecular diagnostics company focused on the development and commercialization of innovative detection products. These are used for diagnostic and research applications in the life sciences and healthcare industry.

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.

BMEYE B.V. is a non-invasive cardiovascular monitoring company based in Amsterdam, Netherlands, specializing in the research and development of medical technologies for cardiovascular assessment. The company offers a range of innovative products, including the Finapres, a continuous finger blood pressure monitor, and the Portapres, an ambulatory version of the same technology. Additionally, BMEYE provides the Finometer, which can measure non-invasive brachial pressure and beat-to-beat hemodynamics, along with BeatScope, a software for analyzing arterial pressure waveforms. Other notable products include Modelflow, which computes aortic flow waveform and cardiac output from arterial blood pressure waveforms, and the Nexfin monitor, which measures blood pressure and cardiac output for various medical applications. BMEYE serves a diverse range of fields, including cardiology, anesthesiology, and neurology, through a network of distributors. Founded in 2005, the company was later acquired by Edwards Lifesciences.

Kiadis Pharma is a biopharmaceutical company focused on complications and limitations of hematopoietic stem cell transplants in blood cancer patients. The company has three blood cancer products in clinical development that offer novel treatment options for terminally ill cancer patients addressing high-unmet medical needs. Kiadis Pharma is headquartered in Amsterdam, The Netherlands.

Scandic Hotels Group is a Sweden-based company that engages itself in operation of hotels. It operates more than 200 hotels at close to 120 destinations which give a unique geographic reach for both corporate and leisure travelers. The majority of the company revenue comes from business travel and conferences. The business of the group is operated through various geographical region which includes Sweden, Belgium, Denmark, Finland, Norway, Poland, and Germany out of which Sweden accounts for majority of revenue.

ActoGeniX is a biopharmaceutical company based in Zwijnaarde, Belgium, founded in 2006 by Bernard Coulie and Mark Vaeck. The company specializes in the development and commercialization of innovative biological drugs, utilizing a proprietary technology platform that leverages living non-pathogenic microorganisms for oral delivery of biopharmaceuticals. ActoGeniX aims to address unmet medical needs in gastrointestinal, immunological, and metabolic diseases, contributing to advancements in therapeutic options within these fields.

Prosensa is a biopharmaceutical company that specializes in the discovery, development, and commercialization of RNA-based therapeutics. It is particularly focused on addressing genetic disorders, with a primary emphasis on neuromuscular conditions. The company recognizes significant market opportunities in the healthcare sector for innovative products targeting genetic disorders, anti-infectives, and oncology. To maximize commercial potential, Prosensa plans to leverage its strong intellectual property position while primarily outsourcing its operations to specialized organizations. Through this strategy, the company aims to develop novel therapeutics that can address unmet medical needs in various therapeutic areas.

Movetis NV, a pharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of diseases in the gastrointestinal (GI) area. Its products address GI disorders, such as severe chronic constipation, ascites, paediatric reflux, as well as severe forms of GI motility disorders, including refractory gastro-oesophageal reflux disease. The company's lead product, Resolor, is used for the symptomatic treatment of chronic constipation in women. Resolor is also tested for chronic constipation in males and children, as well as opioid-induced constipation and post operative ileus. Its products also include M0002, which is in Phase II trials to treat ascites, an accumulation of fluid caused by liver malfunction; and M0003 that is entering Phase II development for symptomatic treatment of heartburn and regurgitation in patient's refractory to PPIs, and pediatric reflux. In addition, the company also has two prioritized compounds out of its preclinical portfolio, M0014 and M0012, and two compound libraries. It has partnership agreements with the universities of Ghent, Leuven, and Rotterdam. The company was founded in 2006 and is headquartered in Turnhout, Belgium.

BMEYE B.V. is a non-invasive cardiovascular monitoring company based in Amsterdam, Netherlands, specializing in the research and development of medical technologies for cardiovascular assessment. The company offers a range of innovative products, including the Finapres, a continuous finger blood pressure monitor, and the Portapres, an ambulatory version of the same technology. Additionally, BMEYE provides the Finometer, which can measure non-invasive brachial pressure and beat-to-beat hemodynamics, along with BeatScope, a software for analyzing arterial pressure waveforms. Other notable products include Modelflow, which computes aortic flow waveform and cardiac output from arterial blood pressure waveforms, and the Nexfin monitor, which measures blood pressure and cardiac output for various medical applications. BMEYE serves a diverse range of fields, including cardiology, anesthesiology, and neurology, through a network of distributors. Founded in 2005, the company was later acquired by Edwards Lifesciences.

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

Pronota NV is developing and commercialising first-in-class diagnostics for early detection of life-threatening conditions and unmet medical needs including heart failure, pre-eclampsia and sepsis. Pronota's non-invasive, validated, diagnostics are proprietary and focused on improving quality of care for patients. Backed by a solid base of investors including GIMV, LSP, KBC Private Equity and JJDC, and a wide network of renowned key opinion leaders, Pronota is committed to making a difference in diagnosis and personalized healthcare. Pronota NV was formerly known as Peakadilly NV and changed its name to Pronota NV in November 2006. The company was founded in 2004 and is based in Zwijnaarde, Belgium.

DNage is a life sciences company founded in 2004 as a spin off from the Department of Genetics of the Erasmus Medical Center Rotterdam. The Company was seed-funded through an equity investment of an international syndicate of venture capitalists including LSP (NL) and Inventages (CH).

OctoPlus is a specialty pharmaceutical company globally renowned for its expertise in pharmaceutical development of injectables and is based on the bioscience park, one of the leading bioscience industry parks in Europe. The company employs around 120 people, and is highly culturally diverse, with over 20 different nationalities represented in its workforce.

PamGene has a unique proprietary array-based platform to measure the activities of kinases & nuclear receptors, enabling deeper understanding of drug interactions with these important classes of signalling molecules. PamGene's patented technology finds a wide range of applications including lead identification and optimization, (pre) clinical translational research and biomarker development.

PamGene has a unique proprietary array-based platform to measure the activities of kinases & nuclear receptors, enabling deeper understanding of drug interactions with these important classes of signalling molecules. PamGene's patented technology finds a wide range of applications including lead identification and optimization, (pre) clinical translational research and biomarker development.

Haanpaa provides trucks that distribute chemical products across Europe. It offers services in their storage, maintenance, transportation, and delivery in several European cities. Haanpaa specializes as well in sampling, monitoring, and packaging chemical products. Moreover, it provides tank inspection and customer services. Haanpaa produces specialty chemicals, pulps and papers, fuels, lubricants, animal feeds, agricultural commodities, and other products. Jussi Haanpaa founded Haanpaa in 1949, with its headquarters in Vantaa in Finland. Haanpaa has branches in Oulu and Hamina in Finland; Helsingborg and Göteborg in Sweden, Fredrikstad in Norway, Tallinn in Estonia, Saint Petersburg and Moscow in Russia, and Barendrecht in the Netherlands. It now operates as a subsidiary of Groupe Samat SA since July 12, 2016.